Filing Flows › Biolargo (BLGO) › Q2 2026 › vs Q1 2026
Biolargo (BLGO) Q2 2026 vs Q1 2026 (quarter over quarter)
Biolargo's revenue rose $133K (+12%) from $1.1M in Q1 2026 to $1.2M in Q2 2026. The biggest changes: Service +$289K (+54%); Product −$156K (-27%).
Biolargo, Q2 2026: revenue $1.2M (-55% year over year), operating margin -298.7%, net loss $4.0M, operating cash flow −$3.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Service | $827K | $538K | $289K | +54% |
| Product | $421K | $577K | −$156K | -27% |
| Revenue | $1.2M | $1.1M | $133K | +12% |
| Net loss | $4.0M | $3.4M | $595K | +17% |
| Costs & expenses | $5.2M | $4.5M | $728K | +16% |
| Operating costs | $5.0M | $4.3M | $657K | +15% |
| Interest & other, net | $272K | $201K | $71K | +35% |
| Cost of revenue | $573K | $657K | −$84K | -13% |
| Research & development | $1.1M | $907K | $181K | +20% |
| SG&A | $3.3M | $2.8M | $560K | +20% |
| Operating cash sources | $4.0M | $3.4M | $595K | +17% |
| Depreciation | $31K | $34K | −$3K | -9% |
| Share-based compensation | $722K | $699K | $23K | +3% |
| Working capital & other | $191K | −$245K | $436K | — |
| Cash used in operations | $3.1M | $2.9M | $139K | +5% |
| Net loss absorbed | $4.0M | $3.4M | $595K | +17% |
Questions
How much did Biolargo's revenue grow quarter over quarter in Q2 2026?
Biolargo's revenue rose $133K (+12%) from $1.1M in Q1 2026 to $1.2M in Q2 2026.
What drove Biolargo's revenue change in Q2 2026?
Service +$289K (+54%); Product −$156K (-27%).